Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group


Por: Arrieta, O, Cardona, AF, Lara-Mejia, L, Heredia, D, Barron, F, Zatarain-Barron, ZL, Lozano, F, de Lima, VC, Maldonado, F, Corona-Cruz, F, Ramos, M, Cabrera, L, Martin, C, Corrales, L, Cuello, M, Arroyo-Hernandez, M, Aman, E, Bacon, L, Baez, R, Benitez, S, Botero, A, Burotto, M, Caglevic, C, Ferraris, G, Freitas, H, Kaen, DL, Lamot, S, Lyons, G, Mas, L, Mata, A, Mathias, C, Munoz, A, Patane, AK, Oblitas, G, Pino, L, Raez, LE, Remon, J, Rojas, L, Rolfo, C, Ruiz-Patino, A, Samtani, S, Viola, L, Viteri, S and Rosell, R

Publicada: 1 sep 2020 Ahead of Print: 20 jun 2020
Resumen:
The world currently faces a pandemic due to SARS-CoV-2. Relevant information has emerged regarding the higher risk of poor outcomes in lung cancer patients. As such, lung cancer patients must be prioritized in terms of prevention, detection and treatment. On May 7th, 45 experts in thoracic cancers from 11 different countries were invited to participate. A core panel of experts regarding thoracic oncology care amidst the pandemic gathered virtually, and a total of 60 initial recommendations were drafted based on available evidence, 2 questions were deleted due to conflicting evidence. By May 16th, 44 experts had agreed to participate, and voted on each of the 58 recommendation using a Delphi panel on a live voting event. Consensus was reached regarding the recommendations (> 66 % strongly agree/agree) for 56 questions. Strong consensus (> 80 % strongly agree/agree) was reached for 44 questions. Patients with lung cancer represent a particularly vulnerable population during this time. Special care must be taken to maintain treatment while avoiding exposure.

Filiaciones:
Arrieta, O:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Cardona, AF:
 Thorac Oncol Clin, Clin Country, Bogota, Colombia

 Fdn Clin & Appl Canc Res, Bogota, Colombia

Lara-Mejia, L:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Heredia, D:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Barron, F:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Zatarain-Barron, ZL:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Lozano, F:
 Inst Natl Cancerol, Mexico City, DF, Mexico

de Lima, VC:
 A C Camargo Canc Ctr, Dept Oncol Clin, Sao Paulo, Brazil

Maldonado, F:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Corona-Cruz, F:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Ramos, M:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Cabrera, L:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Martin, C:
 Alexander Fleming Inst, Thorac Oncol Unk, Buenos Aires, DF, Argentina

 Hosp Maria Ferrer, Buenos Aires, DF, Argentina

Corrales, L:
 Hosp San Juan Dios, Oncol Dept, San Jose Costa Rica, Costa Rica

 Ctr Invest & Manejo Canc CIMCA, Oncol Med, San Jose, Costa Rica

Cuello, M:
 Univ Republ UDELAR, Hosp Clin, Dept Oncol, Montevideo, Uruguay

Arroyo-Hernandez, M:
 Inst Natl Cancerol, Mexico City, DF, Mexico

Aman, E:
 Swiss Med Grp, Clin Oncol Unk, Buenos Aires, DF, Argentina

Bacon, L:
 Hosp Vivian Pallas, Ctr Oncol, Managua, Nicaragua

Baez, R:
 Natl Inst Resp Dis, Mexico City, DF, Mexico

Benitez, S:
 Assoc Argentina Med Resp, Coordinador Secc Oncol, Buenos Aires, DF, Argentina

Botero, A:
 Hosp La Catolica Goicoechea, San Jose, Costa Rica

Burotto, M:
 Clin Univ Andes, Ctr Estudios Clin Bradford Hill, Santiago, Chile

Caglevic, C:
 Fdn Arturo Lopez Perez, Dept Invest Canc, Santiago, Chile

Ferraris, G:
 Ctr Med Dean Funes, Radioterapia Oncol, Cordoba, Argentina

Freitas, H:
 A C Camargo Canc Ctr, Dept Oncol Clin, Sao Paulo, Brazil

Kaen, DL:
 Ctr Oncol Riojano Integral, La Rioja, Argentina

Lamot, S:
 Inst Oncohematol Patagonia, CONCIENCIA, Rio Verde, Chile

Lyons, G:
 Hosp Britanico, Dept Thorac Surg, Buenos Aires, DF, Argentina

Mas, L:
 Natl Inst Neoplast Dis INEN, Med Oncol Dept, Lima, Peru

Mata, A:
 Hosp La Catolica Goicoechea, San Jose, Costa Rica

Mathias, C:
 NOB Oncoclin, Salvador, BA, Brazil

Munoz, A:
 Fdn Santa Fe Bogota, Bogota, Colombia

Patane, AK:
 Hosp Rehabil Resp Maria Ferrer, Buenos Aires, DF, Argentina

Oblitas, G:
 Unidad Oncol Mol Peruana, Lima, Peru

Pino, L:
 Fdn Santa Fe Bogota, Med Oncol Grp, Bogota, Colombia

Raez, LE:
 Mem Healthcare Syst, Thorac Oncol Program, Mem Canc Inst, Pembroke Pines, FL USA

Remon, J:
 HM Delfos, Ctr Integral Oncol Clara Campal Bacelona, Med Oncol Dept, Barcelona, Spain

Rojas, L:
 Clin Colsanitas, Med Oncol Dept, Bogota, Colombia

Rolfo, C:
 Univ Maryland, Sch Med, Marlene & Stewart Greenbaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

Ruiz-Patino, A:
 Fdn Clin & Appl Canc Res, Bogota, Colombia

Samtani, S:
 Clin Bradford Hill, Med Oncol Dept, Santiago, Chile

Viola, L:
 Fdn Neumol Colombiana, Bogota, Colombia

Viteri, S:
 Inst Oncol Dr Rosell, Ctr Med Teknon, Grp QuironSalud, Barcelona, Spain

:
 Hosp Germans Trias i Pujol, Catalan Inst Oncol, Canc Biol & Precis Med Program, Barcelona, Spain
ISSN: 10408428





CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Editorial
Elsevier BV, STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA, Países Bajos
Tipo de documento: Review
Volumen: 153 Número:
Páginas: 103033-103033
WOS Id: 000572848600008
ID de PubMed: 32650215
imagen Bronze, Green Published

MÉTRICAS